Biogen Inc. Files 8-K: Director & Officer Changes
Ticker: BIIB · Form: 8-K · Filed: 2024-10-30T00:00:00.000Z
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes
Related Tickers: BIIB
TL;DR
Biogen filed an 8-K on Oct 28th for director/officer changes & comp. Nothing major yet.
AI Summary
Biogen Inc. filed an 8-K on October 30, 2024, reporting changes in its board of directors and certain officers, along with updates to compensatory arrangements. The filing also includes Regulation FD disclosures and financial statements/exhibits. The earliest event reported was on October 28, 2024.
Why It Matters
Changes in a company's board and executive officers can signal shifts in strategy or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing primarily concerns routine corporate governance updates and disclosures, not immediate financial distress or significant operational changes.
Key Players & Entities
- Biogen Inc. (company) — Registrant
- October 28, 2024 (date) — Earliest event reported
- October 30, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Cambridge, Massachusetts (location) — Business address
FAQ
What specific changes were made regarding directors or officers?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' and 'Compensatory Arrangements of Certain Officers', but the specific details of these changes are not provided in the provided text.
What is the significance of the 'Regulation FD Disclosure' item?
This item indicates that Biogen Inc. is making public disclosures in accordance with Regulation Fair Disclosure, ensuring that material information is broadly disseminated to the public.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this filing was on October 28, 2024.
What is Biogen Inc.'s primary business classification?
Biogen Inc. is classified under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' with SIC code [2836].
What is the company's fiscal year end?
Biogen Inc.'s fiscal year ends on December 31.
Filing Stats: 1,048 words · 4 min read · ~3 pages · Grade level 10.4 · Accepted 2024-10-30 16:45:53
Key Financial Figures
- $0.0005 — ange on which registered Common Stock, $0.0005 par value BIIB The Nasdaq Global Se
- $750,000 — tts. Ms. Kramer's base salary will be $750,000 and she is eligible to participate in t
- $3,750,000 — ve ("LTI") grant value for 2025 will be $3,750,000, which will be granted in accordance wi
Filing Documents
- d890797d8k.htm (8-K) — 27KB
- d890797dex101.htm (EX-10.1) — 9KB
- d890797dex991.htm (EX-99.1) — 13KB
- g890797g1028031449905.jpg (GRAPHIC) — 2KB
- g890797g1028042044328.jpg (GRAPHIC) — 3KB
- g890797g65c10.jpg (GRAPHIC) — 7KB
- 0001193125-24-247628.txt ( ) — 197KB
- biib-20241028.xsd (EX-101.SCH) — 3KB
- biib-20241028_lab.xml (EX-101.LAB) — 17KB
- biib-20241028_pre.xml (EX-101.PRE) — 11KB
- d890797d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits The exhibit listed on the Exhibit Index below is furnished as part of this Current Report on Form 8-K. Exhibit No. Description 10.1 Letter regarding employment arrangement of Robin Kramer dated October 28, 2024 99.1 Biogen's press release dated October 28, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) - 2 -
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Biogen Inc. By: /s/ Wendell Taylor Wendell Taylor Secretary Date: October 30, 2024 - 3 -